Amivantamab+Lazertinib

At the 2024 ASCO Annual Meeting, data from the final analysis of cohort C demonstrated clinically meaningful and durable antitumor activity with the combination of amivantamab and lazertinib in patients who were treatment-naive or had experienced disease progression on afatinib. Among all patients in cohort C (n = 105), the combination therapy showed an objective response rate (ORR) of 52% (95% CI, 42%-62%), with a median duration of response (DOR) of 14.1 months (95% Ci, 9.5-26.2) and a median progression-free survival (PFS) of 11.1 months (95% CI, 7.8-17.8).

In the first-line setting (n = 49), the combination therapy produced an ORR of 57% (95% CI, 42%-71%) and a median DOR of 20.7 months (95% CI, 9.9-not evaluable [NE]). At a median follow-up of 17.3 months (range, 0.1-31.5), the median PFS with the combination was 19.5 months (95% CI, 11.2-NE), which is notably longer than that reported with classical EGFR TKIs. In the second- and third-line settings (n = 56), the combination also demonstrated significant activity. At a median follow-up of 15.4 months (range, 0.3-30.8), the ORR was 48% (95% CI, 35%-62%), the median DOR was 11.0 months (95% CI, 4.5-NE), and the median PFS was 7.8 months (95% CI, 5.4-11.1).  Among pts treated with prior afatinib (n = 40), ORR was 45% (95% CI, 29–62), with mDoR of 8.9 mo (95% CI, 2.8–NE) and mPFS of 5.7 mo (95% CI, 4.2–10.7). 

https://www.onclive.com/view/dr-cho-on-amivantamab-plus-lazertinib-in-atypical-egfr-mutated-nsclc